HPLC法测定复方甘草口服溶液中苯甲酸钠的含量

目的 建立HPLC法测定复方甘草口服溶液中苯甲酸钠含量的方法.方法 采用高效液相色谱法,色谱柱为Hypersil ODS2(4.6mm×150mm,5μm),以0.02mol·L-1乙酸胺溶液-甲醇(95∶5)为流动相,流速为1.0mL·min-1,检测波长为230nm.结果 在上述色谱条件下,苯甲酸钠在14.56～82.72μg范围内线性关系良好,平均回收率为98.7%,RSD为0.73%(n=6).结论 本方法操作简单,准确,重现性好,为控制复方甘草口服溶液中防腐剂苯甲酸钠的质量提供了重要依据.     

UPLC-TOF-MS法鉴定胀果甘草药渣中黄酮类成分

目的建立胀果甘草药渣中黄酮类成分的超高效液相色谱-高分辨飞行时间质谱(UPLC-TOF-MS)定性分析方法。方法 AgilentSB-C18柱(100mm×4.6mm,1.8μm);流动相乙腈-0.1%甲酸水溶液,梯度洗脱;体积流量0.4mL/min;柱温25℃;检测波长254nm。ESI离子源,飞行时间质谱检测器。对比自制对照品进行鉴别。结果共鉴定出8个黄酮类成分,分别为2’,4,4’-三羟基查耳酮、甘草查耳酮D、甘草查耳酮甲、4’-羟基-2’’,2’’-二甲基吡喃[5’’,6’’,6,7]黄酮、甘草黄酮C、光甘草酮、甘草黄酮B和kanzonolE。结论建立了一种简单、可靠的UPLC-TOF-MS方法对胀果甘草药渣中黄酮类成分进行了鉴定,对胀果甘草药渣综合利用有一定参考价值。     

乌拉尔甘草EST资源的SSR信息分析

目的:为了在乌拉尔甘草中开发功能性EST-SSR分子标记,分析乌拉尔甘草EST-SSRs特征。方法:从NCBI公共数据库中下载乌拉尔甘草EST序列,运用DNAstar软件中的Seqman Pro程序,对下载序列进行拼接和聚类,去除冗余序列,利用SSRIT软件筛选重复序列长度≥20 bp的二、三、四、五核苷酸4种类型的SSR,统计分析乌拉尔甘草EST-SSR的特征。结果:从NCBI公共数据库中下载50666条乌拉尔甘草EST序列,剔除冗余序列,得到全长为9.28×106bp的无冗余EST序列11100条。在这些序列中搜索出752条EST序列含有963个SSR,占无冗余EST序列的8.68%,平均每9.64 kb EST出现1个SSR位点。二核苷酸重复基元SSR出现频率最高(43.41%),其次是三核苷酸(41.95%),AG/TC、GA/CT和CTT/GAA是二、三核苷酸中的优势重复基元。乌拉尔甘草EST-SSR以4～10次重复为主,基序长度主要集中于20～30bp。结论:乌拉尔甘草EST-SSR的出现频率高,重复类型丰富,理论上表明这些EST-SSR具有较高的可用性。本文通过对乌拉尔甘草EST资源的SSR信息的研究,为分子水平和生物信息学角度上开发乌拉尔甘草的SSR功能性标记提供了候选序列。     

冠状动脉慢血流现象临床危险因素及形态学研究

目的探寻冠状动脉慢血流现象(CSFP)的临床危险因素,了解冠状动脉形态对心肌梗死溶栓治疗试验(TIMI)血流的影响,推测CSFP的发病机制。方法回顾性收集2017年1月至2019年7月于兰州大学第一医院心脏中心行冠状动脉造影无狭窄病变的患者256例,根据TIMI血流帧数将其中血流减慢的患者设为CSFP组(100例),将血流正常患者设为对照组(156例),按年龄和性别匹配。收集患者临床数据和冠状动脉造影数据,采用二元logistic回归模型分析CSFP的危险因素,并采用Pearson相关分析检验冠状动脉形态学参数与平均校正的TIMI帧数(cTFC)的相关性。结果CSFP组同型半胱氨酸[(22.07±7.27)mmol/L比(18.16±6.63)mmol/L]、中性粒细胞百分比[(44.40±15.60)%比(35.43±12.49)%]、淋巴细胞百分比[3.65%(1.32%,24.65%)比1.80%(1.02%,6.22%)]、平均血小板体积(MPV)[(13.17±1.82)fl比(12.20±1.57)fl]、血小板分布宽度(PDW)[(14.17±2.17)f l比(13.21±2.42)f l]与对照组相比更高,三酰甘油[(3.05±1.37)mmol/L比(3.44±1.36)mmol/L]、纤维蛋白原[(2.65±0.68)g/L比(2.86±0.66)g/L]与对照组相比更低,术中血压更低,冠状动脉平均直径更大,平均远端分支数更少,差异均有统计学意义(均P<0.05)。二元logistic回归模型拟合显示:同型半胱氨酸(OR 1.077,95%CI 1.034~1.123,P<0.001)、中性粒细胞百分比(OR 1.064,95%CI 1.032~1.097,P<0.001)、PDW(OR 1.194,95%CI 1.051~1.356,P=0.006)、MPV(OR 1.338,95%CI 1.127~1.588,P=0.001)是预测CSFP的独立危险因素。相关性分析显示,冠状动脉平均直径与平均cTFC呈显著正相关(r=0.583,P<0.05);冠状动脉平均远端分支数与平均cTFC呈显著负相关(r=-0.508,P<0.05)。结论同型半胱氨酸、中性粒细胞百分比、PDW和MPV是预测CSPF的独立危险因素。冠状动脉平均直径和远端分支数均与冠状动脉平均cTFC密切相关。炎症可能是CSFP发生的关键机制。     

Antioxidant therapy for chronic hepatitis C after failure of interferon: Results of phase Ⅱ randomized, double-blind placebo controlled clinical trial

AIM: To assess the safety and efficacy of antioxidant therapy for patients with chronic hepatitis C virus (HCV) infection. METHODS: One hundred chronic HCV infection patients failed in interferon treatment were enrolled and randomly assigned to receive combined intravenous and oral antioxidants or placebo, or oral treatment alone. Primary end points were liver enzymes, HCV-RNA levels and histology. RESULTS: Combined oral and intravenous antioxidant therapy was associated with a significant decline in ALT levels in 52% of patients who received antioxidant therapy vs 20% of patients who received placebo (P = 0.05). Histology activity index (HAI) score at the end of treatment was reduced in 48% of patients who received antioxidant therapy vs 26% of patients who received placebo (P = 0.21). HCV-RNA levels decreased by 1-log or more in 28% of patients who received antioxidant therapy vs 12% who received placebo (P = NS). In part Ⅱ of the trial, oral administration of antioxidants was not associated with significant alterations in any of the end points. CONCLUSION: Antioxidant therapy has a mild beneficial effect on the inflammatory response of chronic HCV infection patients who are non-responders to interferon. Combined antiviral and antioxidant therapy may be beneficial for these patients.     

甘草Lx对青霉噻唑蛋白致敏大鼠过敏休克的保护作用

为寻找青霉素类过敏休克有效防治药物,研究了甘草Lx对青霉噻唑(BPO)-蛋白致敏大鼠过敏休克的保护作用。结果表明:大鼠腹腔注射甘草Lx,可明显降低BPO-蛋白致敏大鼠过敏休克发生率和死亡率,致敏对照组过敏休克发生率和死亡率分别为100%和70%,给药组均为5%。致敏对照组和Lx给药组大鼠血清抗体峰效价分别为96和4,肺组胺含量分别为99±6和64±8ng/g(P<0.01)。提示甘草Lx的保护作用可能与抑制致敏大鼠抗体生成和肺组胺合成有关。     

Pharmacological Effects of Glycyrrhiza spp. and Its Bioactive Constituents: Update and Review

The roots and rhizomes of various species of the perennial herb licorice (Glycyrrhiza) are used in traditional medicine for the treatment of several diseases. In experimental and clinical studies, licorice has been shown to have several pharmacological properties including antiinflammatory, antiviral, antimicrobial, antioxidative, antidiabetic, antiasthma, and anticancer activities as well as immunomodulatory, gastroprotective, hepatoprotective, neuroprotective, and cardioprotective effects. In recent years, several of the biochemical, molecular, and cellular mechanisms of licorice and its active components have also been demonstrated in experimental studies. In this review, we summarized the new phytochemical, pharmacological, and toxicological data from recent experimental and clinical studies of licorice and its bioactive constituents after our previous published review. Copyright © 2015 John Wiley & Sons, Ltd.     

甘草种苗等级与植株生物量积累及药材产量和质量的关系

目的:研究甘草种苗等级与植株生物量积累、药材产量和质量的关系,为制定种苗标准提供依据。方法:以单根重量为分级指标对甘草种苗进行分级,采用聚类分析方法将种苗聚类分级为3个级别,以级别为处理进行田间试验,连续两年于生长期测定甘草植株鲜重和根干重,实验室测定药材有效成分含量。结果:一级、二级种苗(单根重10.0 g以上)生长期植株的总生物量、根干物质量及产量均大于三级种苗。3年生药材的甘草酸、甘草苷、芹糖基甘草苷和甘草素的含量,一、二级种苗高于三级种苗;不同等级种苗药材甘草酸和甘草苷的含量均高于2010年版中国药典一部标准。结论:种苗等级对甘草药材的质量及产量均有影响,生产上建议选用单根重在10.0g以上的种苗。